Drugs / MG-S-2525
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03650075 | Feb → Dec 2019 | idiopathic pulmonary fibrosis | Metagone Biotech Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MG-S-2525 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03650075 ↗ |
| Action | Inhibit | “an inhibitor of MAP3K19” NCT03650075 ↗ |
| Modality | Small molecule | “which is an oral, small-molecule, anti-inflammatory agent” NCT03650075 ↗ |
| Route | Oral | “which is an oral, small-molecule, anti-inflammatory agent” NCT03650075 ↗ |
| Target | MAP3K19 | “an inhibitor of MAP3K19” NCT03650075 ↗ |